Advancing care in rare kidney diseases – reflections from ERA Congress

12 June, 2025 08:30

Each year, the European Renal Association (ERA) Congress brings together experts, researchers, and industry partners to share the latest scientific advances and highlight continued needs in kidney disease care. This year’s congress in Vienna, Austria, highlighted both the progress and the ongoing need for innovation in the field of rare kidney diseases, a focus area where Sobi is proud to contribute.

While treatment options for many common diseases have advanced significantly, the reality is different for people living with rare diseases. Diagnosis is often delayed, and targeted treatment options are limited or still in development.

Rare kidney diseases illustrate this challenge well. Although each rare condition affects relatively few individuals, collectively, rare diseases impact an estimated 30 million people in Europe alone. In nephrology, progress over the past decade has been encouraging, with growing research and more approved therapies. Yet for many rare kidney diseases, disease-modifying treatments are still urgently needed.

Discussions at this year’s ERA Congress made it clear: sustained collaboration across research, clinical care, and industry is essential to further advance treatment and improve outcomes for people affected by these conditions.

At Sobi, we are committed to supporting this effort. We focus on developing innovative therapies for rare and debilitating diseases, including rare renal diseases that often affect children. We believe that by working closely with the nephrology community, researchers, healthcare professionals, and advocacy groups, we can help drive continued progress.

The conversations at ERA reinforced the need for sustained commitment. We left the congress energised by the progress being made and determined to keep driving forward. We remain committed to working with the nephrology community to advance care and improve outcomes for people living with rare kidney diseases.

/Lydia Abad-Franch, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi.

Advancing care in rare kidney diseases – reflections from ERA Congress

© Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321